1European Helicobacter Study Group.Current European concepts in the management of Helicobacter pylori infections,The Maastricht Consensus Report.Gut,1997,41:8-13.
2Malfertheiner P,M'egraud F,O' Morain C,et al.European Helicobacter pylori Study Group (EHPSG).Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 Consensus Report.Aliment Pharmacol Ther,2002,16:167-180.
3Graham DY.Antibiotic resistance in Helicobacter pylori:implications for therapy.Gastroenterology,1998,115:1272-1277.
4Buckley MJ,Xia HX,Hyde DM,et al.Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.Dig Dis Sci,1997,42(10):2111-2115.
5Tankovic J,Lamarque D,Lascols C,et al.Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillinclarithromycin therapy.Aliment Pharmacol Ther,2001,15(5):707-713.
6Ling TK,Cheng AF,Sung JJ,et al.An increase in Helicobacter pylori strains resistant to metronidazole:a five-year study.Helicobacter,1996,1(1):57-61.
7Wang WH,Wong BC,Mukhopadhyay AK,et al.High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong.Aliment Pharmacol Ther.2000,14(7):901-910.
8Heep M,Kist M,Strobel S,et al.Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy.Eur J Clin Microbiol Infect Dis.2000,19(7):538-541.
9Davis R,Bryson HM.Levofloxacin.A review of its antibacterial activity,pharmacokietics and therapeutic efficacy.Drugs,1994,47:677-700.
10Cammarota G,Cianci R,Cannizzaro O,et al.Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.Aliment Pharmacol Ther,2000,14(10):1339-1343.
